Open Label, Randomized, Multicentric, Comparative and Controlled Clinical Trial to Compare the Efficacy and Toxicity of Mycobacterium w Intra-dermal to Intravesical BCG in Patients With Newly Diagnosed Superficial Transitional Cell Carcinoma With High Probability of Recurrence.

Trial Profile

Open Label, Randomized, Multicentric, Comparative and Controlled Clinical Trial to Compare the Efficacy and Toxicity of Mycobacterium w Intra-dermal to Intravesical BCG in Patients With Newly Diagnosed Superficial Transitional Cell Carcinoma With High Probability of Recurrence.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Cadi 05 (Primary) ; BCG
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cadila Pharmaceuticals
  • Most Recent Events

    • 09 Mar 2012 Actual patient number 122 added as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Planned end date changed from 1 Aug 2011 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top